MedTrace Logo

A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.

NCT02264535 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2014-12-02

No results posted yet for this study

Summary

This pilot study is designed to explore the optimal concentration and method of Ginkgolides Meglumine Injection skin testing and to evaluate the value of skin test in predicting any possible allergic reactions to Ginkgolides Meglumine Injection.

Conditions

  • Allergy

Interventions

DRUG

0.1mg/ml Ginkgolides Meglumine Injection

DRUG

1mg/ml Ginkgolides Meglumine Injection

DRUG

5mg/ml Ginkgolides Meglumine Injection

Sponsors & Collaborators

  • Beijing Bionovo Medicine Development Co., Ltd.

    collaborator OTHER

  • Jiangsu Kanion Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yuhong Huang · Second Affiliated Hospital of Tianjin University of TCM

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264535 on ClinicalTrials.gov